Immune checkpoint blockade (ICB) therapy, which enhances antitumor immune response by using antibodies blocking inhibitory immune-checkpoint proteins such as programmed cell death protein 1 (PD-1) and its ligand PD-L1, has demonstrated significant clinical benefit for NSCLC [8,9]. Here, PDCD1 is linked to non-small cell lung carcinoma.